Skip to main content
Journal cover image

Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up.

Publication ,  Journal Article
El-Chami, MF; Bockstedt, L; Longacre, C; Higuera, L; Stromberg, K; Crossley, G; Kowal, RC; Piccini, JP
Published in: Eur Heart J
March 21, 2022

AIMS: Clinical trials have demonstrated the safety and efficacy of the Micra leadless VVI pacemaker; however, longer-term outcomes in a large, real-world population with a contemporaneous comparison to transvenous VVI pacemakers have not been examined. We compared reinterventions, chronic complications, and all-cause mortality at 2 years between leadless VVI and transvenous VVI implanted patients. METHODS AND RESULTS: The Micra Coverage with Evidence Development study is a continuously enrolling, observational, cohort study of leadless VVI pacemakers in the US Medicare fee-for-service population. Patients implanted with a leadless VVI pacemaker between March 9, 2017, and December 31, 2018, were identified using Medicare claims data linked to manufacturer device registration data (n = 6219). All transvenous VVI patients from facilities with leadless VVI implants during the study period were obtained directly from Medicare claims (n = 10 212). Cox models were used to compare 2-year outcomes between groups. Compared to transvenous VVI, patients with leadless VVI had more end-stage renal disease (12.0% vs. 2.3%) and a higher Charlson comorbidity index (5.1 vs. 4.6). Leadless VVI patients had significantly fewer reinterventions [adjusted hazard ratio (HR) 0.62, 95% confidence interval (CI) 0.45-0.85, P = 0.003] and chronic complications (adjusted HR 0.69, 95% CI 0.60-0.81, P < 0.0001) compared with transvenous VVI patients. Adjusted all-cause mortality at 2 years was not different between the two groups (adjusted HR 0.97, 95% CI 0.91-1.04, P = 0.37). CONCLUSION: In a real-world study of US Medicare patients, the Micra leadless VVI pacemaker was associated with a 38% lower adjusted rate of reinterventions and a 31% lower adjusted rate of chronic complications compared with transvenous VVI pacing. There was no difference in adjusted all-cause mortality at 2 years.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur Heart J

DOI

EISSN

1522-9645

Publication Date

March 21, 2022

Volume

43

Issue

12

Start / End Page

1207 / 1215

Location

England

Related Subject Headings

  • United States
  • Treatment Outcome
  • Pacemaker, Artificial
  • Medicare
  • Humans
  • Follow-Up Studies
  • Equipment Design
  • Cohort Studies
  • Cardiovascular System & Hematology
  • Cardiac Pacing, Artificial
 

Citation

APA
Chicago
ICMJE
MLA
NLM
El-Chami, M. F., Bockstedt, L., Longacre, C., Higuera, L., Stromberg, K., Crossley, G., … Piccini, J. P. (2022). Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up. Eur Heart J, 43(12), 1207–1215. https://doi.org/10.1093/eurheartj/ehab767
El-Chami, Mikhael F., Lindsay Bockstedt, Colleen Longacre, Lucas Higuera, Kurt Stromberg, George Crossley, Robert C. Kowal, and Jonathan P. Piccini. “Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up.Eur Heart J 43, no. 12 (March 21, 2022): 1207–15. https://doi.org/10.1093/eurheartj/ehab767.
El-Chami MF, Bockstedt L, Longacre C, Higuera L, Stromberg K, Crossley G, et al. Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up. Eur Heart J. 2022 Mar 21;43(12):1207–15.
El-Chami, Mikhael F., et al. “Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up.Eur Heart J, vol. 43, no. 12, Mar. 2022, pp. 1207–15. Pubmed, doi:10.1093/eurheartj/ehab767.
El-Chami MF, Bockstedt L, Longacre C, Higuera L, Stromberg K, Crossley G, Kowal RC, Piccini JP. Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up. Eur Heart J. 2022 Mar 21;43(12):1207–1215.
Journal cover image

Published In

Eur Heart J

DOI

EISSN

1522-9645

Publication Date

March 21, 2022

Volume

43

Issue

12

Start / End Page

1207 / 1215

Location

England

Related Subject Headings

  • United States
  • Treatment Outcome
  • Pacemaker, Artificial
  • Medicare
  • Humans
  • Follow-Up Studies
  • Equipment Design
  • Cohort Studies
  • Cardiovascular System & Hematology
  • Cardiac Pacing, Artificial